Korea Joongang Daily
Korea JoongAng Daily

SK Biopharmaceuticals, Eurofarma to launch telehealth joint venture

SK Biopharmaceuticals and Eurofarma formed a joint venture to develop an AI platform for managing epilepsy. The focus includes real-time seizure prediction and a community for patient communication.

2025-01-15

SK Biopharmaceuticals returns to profit as epilepsy drug boosts bottom line

SK Biopharmaceuticals swung to black in the fourth quarter last year with expectation-beating results. Its annual operating loss got smaller as well, driven by strong sales of its epilepsy drug Xcopri, according to the drugmaker.

2024-01-29

SK Biopharm expects turnaround year with potential 'blockbuster' drug

SK Biopharmaceuticals expects positive cash flow from the epilepsy drug Xcopri, and aims for $2 billion in sales by 2029.

2024-01-10

Korean pharma shines at global health care conference

Korean biopharma shines at J.P. Morgan Healthcare Conference amid global industry optimism.

2024-01-09

SK Biopharmaceuticals aims to become 'big biotech'

The Seongnam, Gyeonggi-based biopharmaceutical company expects to swing back into profit next year with global sales of Cenobamate, and hopes to achieve an enterprise value of $15 billion by 2026.

2023-07-18

SK Biopharmaceuticals acquires majority share of U.S biotech firm

SK Biopharmaceuticals has acquired 60 percent of U.S. biotech company Proteovant Therapeutics for $47.5 million, the company said on Friday.

2023-06-30

SK Biopharmaceuticals' epilepsy drug wins use approval from Canada

SK Biopharmaceuticals' epilepsy drug Cenobamate won use approval from Canada, the Korean company said Thursday.

2023-06-15

SK Pharmteco announces delay in Nasdaq listing

SK Pharmteco will push back its plan to list on the Nasdaq to as early as 2024, after the markets have had time to recover from the current downturn

2023-01-13

SK Biopharm to showcase wearable devices for epilepsy patients at CES 2023

SK Biopharmaceuticals will showcase five wearable devices for epilepsy patients at the CES 2023 scheduled for Jan. 5 in Las Vegas.

2022-12-14

SK Biopharmaceuticals reports 15 billion won of net loss in Q3

SK Biopharmaceuticals was in the red in the third quarter, reporting 15 billion won ($11 million) of net loss.

2022-11-10